In the present study, we have demonstrated that 17-aminogeldanamycin inhibits a constitutive p65/NF-κB activity in BRAFV600E and NRASQ61R melanoma cell lines that is evidenced by (i) attenuation of the level of phosphorylated p65/NF-κB subunit, (ii) decrease of transcript levels of NF-κB-dependent genes, including CCND1, CXCL8, and VEGF, (iii) diminution of the level of corresponding proteins in melanoma cells, as well as (iv) reduced secretion of IL-8 and VEGF. This evidence concerns the gene CCND1 and melanoma.